Study protocol of short versus long-term levetiracetam in brain tumors (LIBRA): a phase 3 randomized controlled trial.

ABSTRACT:

Background

Seizures are common in patients with brain tumors, impacting daily life and healthcare burden. In contemporary neuro-oncology practice, levetiracetam is the most commonly prescribed anti-seizure medication (ASM). Although the practice is widely variable, levetiracetam is usually used for 2-3 years following surgery to prevent further seizures. However, the incidence of seizures post antitumoral treatment is relatively low, and the duration of use is not well defined. To address this knowledge gap, the current randomized controlled non-inferiority trial will be conducted comparing a shorter regimen of levetiracetam with the standard long-term schedule.

Methods and analysis

Patients with newly diagnosed primary brain tumors (brain metastasis excluded) in the suprate

SUBMITTER: Dasgupta A 

PROVIDER: S-EPMC12096528 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature